PARSIPPANY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis
NEWTOWN, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Avis Rent A Car System LLC (“Avis”). Avis learned
PARSIPPANY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis
Edelson Lechtzin LLP is investigating claims regarding data privacy violations by Avis Rent A Car System LLC ("Avis"). Avis learned of suspicious activity on or about August 5, 2024.
OKLAHOMA CITY, Okla., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Murphy Law Firm is investigating claims on behalf of all individuals whose personal and confidential information was compromised in the data br
Car rental giant Avis is notifying hundreds of thousands of people that their personal information and driver's license numbers were stolen in an August cyberattack.
Canadian Apartment Properties REIT's Q2 2024 results highlighted a small dip in occupancy, but strong rent growth offset that and pushed NOI margins higher. The sale of the MHC portfolio and a distrib
Latest data from Poseida's lead investigational allogeneic CAR-T program, which is based on the Company's unique stem cell memory T cell (TSCM) platform Company to host conference call on Saturday, Se
Reactivation of P-BCMA-101 CAR-T cells and a repeat stringent complete response (sCR) more than 3 years after original CAR-T therapy Demonstrates potential of stem cell memory T cells (TSCM), a key d
SAN JOSE, Calif. , Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today an
Descartes-15 observed to achieve an approximately ten-fold increase relative to Descartes-08 in CAR expression and selective target-specific killing in preclinical studies
Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, l
Galapagos NV achieved positive results from its European phase 1/2 ATLANTA-1 study using GLPG5101 for patients with relapsed/refractory NHL; phase 1 portion with 87.5% ORR and phase 2 portion with 93.
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA)
CAPREIT's operational performance remains solid, but Northview Residential REIT offers a more attractive risk/return profile in the Canadian residential REIT sector. Earnings update shows solid AMR gr
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE